However, it was the late-breaking Phase 1/2 data from the SOHO-01 study of sevabertinib (BAY 2927088) in advanced HER2-mutant non-small cell lung cancer that pharmaphorum spoke about with Dr Nicoletta ...

GSK and Spero Therapeutics' oral cabapenem, tebipenem HBr, has become the first antibiotic in the class to show efficacy in a ...

Hevia and Sousa discuss the landscape of unmet needs in metastatic castration-resistant prostate cancer, what the new data ...

Alex and Schnappauf explain how Vault CRM is a step-change for companies like Bayer, and discuss the benefits of being able ...

A wireless retinal implant has been shown to restore vision in patients with geographic atrophy (GA), a major cause of ...

Akeso and Summit Therapeutics have shared the full data from the HARMONi-6 trial of PD-1xVEGF bispecific ivonescimab as a ...

AstraZeneca and Daiichi Sankyo's Datroway (datopotamab deruxtecan) came out of the blocks strongly at the ESMO congress with ...

Insmed's DPP1 inhibitor Brinsupri (brensocatib) has been recommended by the CHMP for the treatment of patients aged 12 and ...

Roche has taken a lead in the oral SERD category of breast cancer therapies with the presentation of new data at ESMO showing ...

Amgen and AstraZeneca's Tezspire has claimed FDA approval as a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP ...

In an era where the biopharmaceutical landscape is rapidly evolving, a comprehensive approach to demonstrating and ...